BioCina is a biologics contract development and manufacturing organization (CDMO) that provides scientific and operational services for the development and manufacture of microbial, pDNA, and mRNA-based vaccines.

BioCina

BioCina | 4,604 followers on LinkedIn. Global end-to-end biologics CDMO, offering process development and cGMP clinical and commercial manufacturing | BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical &amp; commercial manufacturing of the microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia is a testament to the quality of its work. It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME’s with an average tenure of 15+ years at the site.

Chief Executive Officer at BioCina and Member of Board of Directors for NovaCina and LumaCina

Mark W. Womack

Business Development Director l Building Strategic Alliances & Driving Growth for Better Patient Outcomes

Rik Quaghebeur

Project Manager | Pharmaceuticals & Biotech professional | Supporting Healthcare & Life Sciences growth and innovation to improve people's lifes

Karla Riquelme Barrera

Vice President, Business Development and Commercial Operations

Jan Bekker

Recapping BioCina at AusBiotech 2024 Last week, some members of our Business Development team, including CEO Mark W. Womack , VP of Business Development & Commercial Operations Jan Bekker , and Sales Specialist Vanessa Kee , had the opportunity to attend AusBiotech 2024 in Melbourne. It was great to meet with current and future clients and partners as well as industry leaders in the Australian and broader biotech community. Our CEO Mark W. Womack shared his insights during a panel hosted by Cytiva on “Bridging the Valley: From Bench to Early Phase.” Joined by Helen Benham from Translational Research Institute Australia and Patrick James from CSIRO . They discussed their perspectives on advancing discovery research in the Australian ecosystem. Mark also shared further strategies for researchers bringing their new therapeutics into the market. A big thank you to everyone in the Australian and international biotech industry that we engaged with. We look forward to more ahead! Check out some highlights from the panel session and our team’s interactions at the event! 📸 #BioCina #AusBiotech2024 #Biotech #CDMO #Innovation #Partnerships

Exciting insights from our CEO, Mark W. Womack , in an interview with Nigel Walker ! Mark shares BioCina's achievements so far and a look into our bright future as we expand further in #Biopharma across #Australia . Check out the full interview to hear more about BioCina’s commitment to innovation and excellence! #BioCina #CDMO #Biopharma #LifeSciences #Innovation #Australia #Growth

BioCina is headed to AusBiotech 2024! We’re excited to announce that both Mark W. Womack , CEO of BioCina, and Jan Bekker , VP of Business Development & Commercial Operations, will be attending the largest life sciences event in Australia — #AusBiotech2024 from October 30th to November 1st in Melbourne! Don’t miss the opportunity to connect with Mark and Jan about BioCina's industry-leading CDMO services! In addition, Mark W. Womack will be sharing his insights as part of an expert panel hosted by Cytiva at 2:20PM-3:05PM on Thursday October 31st, discussing "Bridging the valley: From bench to early phase." 📩 Reach out to Mark ( mwomack@biocina.com ) or Jan ( jbekker@biocina.com ) to set up a meeting during the conference. See you in Melbourne! #BioCina #AusBiotech2024 #LifeSciences #BiotechInnovation #Biologics #CDMO #Partnerships #Australia

We’re proud to announce that Mark W. Womack , CEO of BioCina, will be attending and speaking at #AusBiotech2024 , Australia’s largest Life Sciences Conference in Melbourne from October 30th to November 1st! Joining him will be Jan Bekker , our VP of Business Development & Commercial Operations, as we engage with the global biotech community. Mark will be part of an expert panel hosted by Cytiva , sharing invaluable insights on bridging the gap from early-phase clinical trials to commercial success – a pivotal step in advancing human health. We look forward to discussing innovation, our CDMO Programs, and exploring new partnership opportunities. If you’re attending #AusBiotech2024 , be sure to connect with Mark and Jan! ✉️ mwomack@biocina.com ✉️ jbekker@biocina.com #LifeSciences #Biotech #Innovation #BiologicsCDMO #Partnerships #BioCina #Australia #CommercialOperations

Dear All, Please see this very exciting news directly from our CEO, Mark W. Womack ! #SAPremiersBusinessandExportAwards #BioCina #SABusinessChamber #BiologicsCDMO #Microbial #pDNA #mRNA

🌟 Press Release 🌟 We're thrilled to announce that Centivax has selected BioCina as their partner for cGMP manufacturing in the development of their revolutionary universal influenza vaccine, Cent-Flu. This innovative vaccine has demonstrated the ability to provide protection against current, past, and future influenza strains. BioCina’s Chief Executive Officer, Mark W. Womack stated, “We're privileged to support Centivax’s breakthrough approach to sustained flu prevention and we couldn’t be more excited to be their partner of choice to initiate cGMP manufacturing, thus advancing the journey to bring such an important vaccine to market. This is a tremendous opportunity for the BioCina Team to leverage our world-class capabilities in cell line development, cell banking, and cGMP plasmid production." For more details, check out the full press release here ➡ https://lnkd.in/djUSwUiH #BioCina #Centivax #UniversalFluVaccine #CDMO #Biologics #GMP #Vaccines #Innovation #Healthcare #Biotechnology #CentFlu

We are looking for a qualified and skilled Finance Manager with proven leadership experience and a solid understanding of financial management. Join us to make a significant impact.

📢 PR Release: EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment. We are excited to announce a new partnership with drug developer EnGeneIC , for a project including technology transfer, process scale-up and GMP batch manufacture of EnGeneIC’s proprietary ‘EnGeneIC Dream Vector’ (EDV™) nanocells. Our Chief Executive Officer, Mark W. Womack stated, “I’m so very proud for BioCina to be entrusted to advance EnGeneIC’s transformative therapeutic, which has the potential to make a profound impact on previously untreatable cancers.” For more information please see the full press release here 👉 https://lnkd.in/gMyh4Sae

BioCina offers end-to-end #mRNA contract development and manufacturing services. Our expert team brings extensive technical experience in plasmid manufacturing, in-vitro transcription, purification, and LNP encapsulation of mRNA products. We also offer single site solutions for analytical method development, method validation, product characterisation packages and stability studies. To learn more, view our Fact Sheet below for an overview of our mRNA development and clinical and commercial manufacturing services. Contact us today 🤝 https://lnkd.in/eGSsWhnm or info@biocina.com #CDMO #biologics #plasmiddna #pDNA #messengerRNA #microbial

We are thrilled to be GenomeFrontier Therapeutics, Inc. #CDMO partner for their highly innovative CAR-T therapy program, supporting them with process development and GMP manufacturing for minicircle DNA (for transient gene expression) and Plasmid DNA. Through our current work with them, we are very proud that we recently became the only CDMO to have scaled minicircle DNA manufacturing up to large scale and to have to have successfully manufactured GMP batches! Read more on the partnership here: https://lnkd.in/eemaCr2z Learn more about our recent announcement around minicircle DNA technology here: https://lnkd.in/g6ScC-9Q 🚀 Ready to scale-up your science? Let’s partner up! Contact us today: info@biocina.com . #CAR -T #plasmidDNA #pDNA #minicircleDNA #mcDNA #transientgeneexpression

msh id	COM:BIOCINA
symbol	-
name	BioCina
homepage url	https://biocina.com/
country	AU
sector	Healthcare & Health Services
industry	Pharmaceuticals
market	PRIVATE
employee count	101
crunchbase url	https://www.crunchbase.com/organization/biocina
linkedin url	https://au.linkedin.com/company/biocina
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	13.54K
monthly webtraffic growth	1.75
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

BIOC

COM:BIOCINA

BioCina

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-